Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
$26.05
$0.01(0.04%)
At close: 4:00 PM EST
$26.05
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$13.30 - $29.98
Previous CloseN/A
Volume37.78K
Average Volume (3M)700.60K
Market Cap
$1.55B
Enterprise Value$1.17B
Total Cash (Recent Filing)$477.56M
Total Debt (Recent Filing)$387.00K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding59,347,317
10 Day Avg. Volume1,113,637
30 Day Avg. Volume700,595
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)3.42
Price to Sales (P/S)0.00
P/FCF Ratio-14.46
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.93
Forecast
1Y Price Target
$40.20Price Target Upside54.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1b results showed robust and durable molecular responses to ELVN-001 across tested doses, indicating meaningful clinical activity in patients who had received prior therapies.
Differentiated MechanismELVN-001 inhibits the ATP-binding pocket, offering a distinct mechanism that enables treatment of patients resistant to several other BCR::ABL1 inhibitors and strengthens competitive positioning.
Safety And Dose FlexibilityNo new safety signals were observed and the tolerability profile supported flexible dose selection, which can simplify regimen decisions in later-stage trials.
Bears Say
Competitive BenchmarkA rival BCR::ABL1 inhibitor reported higher early response rates, creating a competitive benchmark that could pressure perceptions of ELVN-001's relative efficacy.
Enrollment CompetitionA competitor's anticipated Phase 3 start could divert eligible patients and slow enrollment for Enliven's pivotal trial, risking delays to development timelines.
Program Execution RiskUncertainty around the final Phase 3 trial design and the possibility of clinical setbacks represent material risks to advancing ELVN-001 into pivotal assessment.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $29.98 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.55B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 55 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.113.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 59,347,317 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -0.148%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.20 (54.32% Upside)
$40.20 (54.32% Upside)
Blogger Sentiment
Neutral
ELVN Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.20%
12-Months-Change
Fundamentals
Return on Equity
-25.43%
Trailing 12-Months
Asset Growth
60.72%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$40.20
▲(54.32% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
Cidara Therapeutics
―
Intellia Therapeutics
―
AbCellera Biologics
―